Study of the Usefulness of Dosage and Administration of the Anti-MRSA Drug Arbekacin Sulfate (ABK) Set at a Peak Blood Concentration of 15-20 g/L

Study of the Usefulness of Dosage and Administration of the Anti-MRSA Drug Arbekacin Sulfate (ABK) Set at a Peak Blood Concentration of 15-20 g/L - Study of the Usefulness of Dosage and Administration of ABK Set at a Peak Blood Concentration of 15-20 g/L

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003161

Enrollment

100

Registered

2010-03-01

Start date

2009-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methicillin-resistant Staphylococcus aureus (MRSA) infection

Interventions

Administration of antibiotic(ABK)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients with pneumonia or sepsis that is caused by or suspected of being caused by MRSA that is sensitive to this drug, who have given their consent to this study, and to whom this drug has been administered. However, administration will be discontinued whenever it is confirmed by the results of drug sensitivity testing that it is not sensitive to ABK

Exclusion criteria

Exclusion criteria: 1) Patients who have received any other anti-MRSA drug (VCM, TEIC, LZD) 2) Patients with reduced renal function (creatinine clearance 30 ml/min/1.73 m2 or less) 3) Patients who are pregnant or might be pregnant 4) Patients who themselves or whose blood relatives have hearing loss caused by an aminoglycoside antibiotic, or other form of hearing loss 5) Patients on any form of dialysis (hemodialysis: HD; continuous ambulatory peritoneal dialysis: CAPD; continuous hemodiafiltration, CHDF) 6) Patients whom the physician in charge judges to be unsuitable for any other reason

Design outcomes

Primary

Measure	Time frame
Efficacy rating: The clinical response will be rated as good if symptoms of infection have disappeared or significantly improved, by taking account of body temperature, chest X-ray findings, WBC, CRP, PaO2/FiO2, etc. at baseline and at completion/discontinuation of the treatment.	—

Secondary

Measure	Time frame
Bacteriological response rating: Based on bacterial isolate changes at completion/discontinuation of study treatment compared to baseline, the bacteriological response will be rated as eliminated if the isolate has become eradicated or if symptoms have improved following the treatment, with disappearance of the organism from the initial lesion, and will be rated as diminished if there is a significant decrease of the isolate (by two grade change: from +++ to +).	—

Measure

Time frame

Bacteriological response rating: Based on bacterial isolate changes at completion/discontinuation of study treatment compared to baseline, the bacteriological response will be rated as eliminated if the isolate has become eradicated or if symptoms have improved following the treatment, with disappearance of the organism from the initial lesion, and will be rated as diminished if there is a significant decrease of the isolate (by two grade change: from +++ to +).

—

Countries

Japan

Contacts

Public ContactTetsuya Matsumoto

Tokyo Medical University Department of Microbiology

tetsuya@tokyo-med.ac.jp03-3351-6141

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026